Prevalence and determinants of serum antibodies to SARS-CoV-2 in the general population of the Gardena valley.
COVID-19
Coronavirus
SARS-CoV-2
neutralising antibodies
prevalence
Journal
Epidemiology and infection
ISSN: 1469-4409
Titre abrégé: Epidemiol Infect
Pays: England
ID NLM: 8703737
Informations de publication
Date de publication:
03 08 2021
03 08 2021
Historique:
entrez:
14
10
2021
pubmed:
15
10
2021
medline:
26
10
2021
Statut:
epublish
Résumé
Estimating the spread of SARS-CoV-2 infection in communities is critical. We surveyed 2244 stratified random sample community members of the Gardena valley, a winter touristic area, amidst the first expansion phase of the COVID-19 pandemic in Europe. We measured agreement between Diasorin and Abbott serum bioassay outputs and the Abbott optimal discriminant threshold of serum neutralisation titres with recursive receiver operating characteristic curve. We analytically adjusted serum antibody tests for unbiased seroprevalence estimate and analysed the determinants of infection with non-response weighted multiple logistic regression. SARS-CoV-2 seroprevalence was 26.9% (95% CI 25.2-28.6) by June 2020. The bioassays had a modest agreement with each other. At a lower threshold than the manufacturer's recommended level, the Abbott assay reflected greater discrimination of serum neutralisation capacity. Seropositivity was associated with place and economic activity, not with sex or age. Symptoms like fever and weakness were age-dependent. SARS-CoV-2 mitigation strategies should account for context in high prevalence areas.
Identifiants
pubmed: 34645534
doi: 10.1017/S0950268821001886
pii: S0950268821001886
pmc: PMC8387688
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Immunoglobulin G
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e194Références
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32381641
Nat Microbiol. 2020 Dec;5(12):1598-1607
pubmed: 33106674
Cell. 2021 Jan 7;184(1):169-183.e17
pubmed: 33296701
Clin Microbiol Infect. 2021 Apr;27(4):633.e1-633.e7
pubmed: 33253941
Nat Commun. 2020 Nov 12;11(1):5749
pubmed: 33184277
Science. 2020 Oct 23;370(6515):
pubmed: 32972996
Science. 2021 Jan 15;371(6526):288-292
pubmed: 33293339
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
Cell Rep Med. 2020 Sep 22;1(6):100081
pubmed: 32839763
Emerg Microbes Infect. 2019;8(1):1593-1603
pubmed: 31711379
Circulation. 2020 Nov 3;142(18):1791-1793
pubmed: 32966752
J Clin Microbiol. 2020 Aug 24;58(9):
pubmed: 32580948
Clin Microbiol Infect. 2021 Mar;27(3):331-340
pubmed: 33228974
Am J Epidemiol. 1978 Jan;107(1):71-6
pubmed: 623091
Nature. 2020 Aug;584(7821):425-429
pubmed: 32604404
Biometrics. 1989 Mar;45(1):255-68
pubmed: 2720055
Lancet. 1986 Feb 8;1(8476):307-10
pubmed: 2868172
N Engl J Med. 2020 Jun 11;382(24):2302-2315
pubmed: 32289214
N Engl J Med. 2020 Mar 26;382(13):1194-1196
pubmed: 32074416
Cell. 2021 Feb 18;184(4):861-880
pubmed: 33497610
Science. 2020 Dec 11;370(6522):1339-1343
pubmed: 33159009
Cell. 2020 Dec 10;183(6):1496-1507.e16
pubmed: 33171099
J Infect. 2020 Dec;81(6):e10-e12
pubmed: 32961253
Cancer. 1950 Jan;3(1):32-5
pubmed: 15405679
Cell. 2020 Oct 1;183(1):158-168.e14
pubmed: 32979941
Respir Med. 2010 Feb;104(2):172-9
pubmed: 19857946
Int J Epidemiol. 2021 Jul 19;:
pubmed: 34293141